{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:36:43Z","timestamp":1787589403850,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006292","name":"Infectious Diseases Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immunocompromised individuals face elevated risks of severe COVID-19, yet vaccination guidance for these populations continues to evolve. To support evidence-based decision-making for the 2025\u20132026 respiratory virus season, the Infectious Diseases Society of America (IDSA) convened a multidisciplinary panel to develop rapid guidelines on the use of US-licensed COVID-19 vaccines in adults and children with hematologic malignancies, primary immunodeficiency, autoimmune disease on immunosuppressive therapy, HIV with severe immunosuppression, solid organ transplantation, hematopoietic cell transplantation (HCT), chimeric antigen receptor T-cell therapy (CAR-T), or solid tumor chemotherapy. A systematic evidence review of studies published from June 2024 to July 2025 identified comparative data on vaccine effectiveness and safety. Using the GRADE framework, the panel evaluated 7 observational effectiveness studies and 4 safety-focused studies. Across studies, COVID-19 vaccination was associated with reduced hospitalization (33%\u201356% effectiveness), critical illness, mortality, and COVID-19\u2013related outpatient or emergency care visits. Serious adverse events were rare, and available evidence did not show consistent increases in exacerbations of underlying immunocompromising conditions. Most studies had short follow-up durations, likely reflecting higher-end estimates of vaccine effectiveness. Given moderate certainty of benefit and low certainty of harm, the panel strongly recommends the 2025\u20132026 COVID-19 vaccine for all immunocompromised individuals aged \u22656 months, with timing tailored to immunosuppressive therapy, clinical stability, and community transmission levels. Adjunct strategies\u2014including vaccination of household contacts and early antiviral access\u2014remain essential. Research priorities include defining immunologic correlates of protection, evaluating durability, optimizing vaccine timing, and improving real-world effectiveness and safety data.<\/jats:p>","DOI":"10.1093\/cid\/ciag115","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:37:38Z","timestamp":1771677458000},"page":"i111-i116","source":"Crossref","is-referenced-by-count":4,"title":["IDSA 2025 Guidelines on the Use of Vaccines for the Prevention of Seasonal COVID-19 Infections in Immunocompromised Patients"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2489-2838","authenticated-orcid":false,"given":"Anoma","family":"Nellore","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, NYU Langone Health and the NYU Transplant Institute, New York, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Bajema","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Oregon Health & Science University, Portland, Oregon ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Belden","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Environmental Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Blumberg","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Disease, Department of Pediatrics, University of California, Davis, School of Medicine, Sacramento, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"York","sequence":"additional","affiliation":[{"name":"Clinical Affairs and Practice Guidelines, Infectious Diseases Society of America, Arlington, Virginia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve","family":"Falck-Ytter","sequence":"additional","affiliation":[{"name":"VA Northeast Ohio Healthcare System, Case Western Reserve University , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Baden","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts Division of Infectious Diseases, ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"2026082412161334600_ciag115-B1","doi-asserted-by":"crossref","first-page":"819","DOI":"10.15585\/mmwr.mm7337e2","article-title":"Use of COVID-19 vaccines for persons aged \u22656 months: recommendations of the advisory committee on immunization practices - United States, 2024-2025","volume":"73","author":"Panagiotakopoulos","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026082412161334600_ciag115-B2","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/vaccines11101611","article-title":"Vaccination recommendations in solid organ transplant adult candidates and recipients","volume":"11","author":"Vigan\u00f2","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2026082412161334600_ciag115-B3","author":"American Society of Transplant Surgeons ASoT"},{"key":"2026082412161334600_ciag115-B4"},{"key":"2026082412161334600_ciag115-B5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/vaccines12121449","article-title":"Vaccination after haematopoietic stem cell transplant: a review of the literature and proposed vaccination protocol","volume":"12","author":"Silva-Pinto","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2026082412161334600_ciag115-B6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jtct.2022.09.002","article-title":"Revised guidelines for coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022)","volume":"28","author":"Dioverti","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026082412161334600_ciag115-B7","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/acr.25045","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with Rheumatic and Musculoskeletal Diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026082412161334600_ciag115-B8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3390\/cancers16020379","article-title":"COVID-19 Outcomes in patients with hematologic malignancies in the era of COVID-19 vaccination and the omicron variant","volume":"16","author":"Mart\u00ednez-L\u00f3pez","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026082412161334600_ciag115-B9","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.lanepe.2023.100747","article-title":"Impact of COVID-19 on immunocompromised populations during the omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"2026082412161334600_ciag115-B10","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/annrheumdis-2021-220626","article-title":"Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression","volume":"80","author":"Prendecki","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2026082412161334600_ciag115-B11","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/infdis\/jiad181","article-title":"The burden of COVID-19 in the immunocompromised patient: implications for vaccination and needs for the future","volume":"228","author":"Antinori","year":"2023","journal-title":"J Infect Dis"},{"key":"2026082412161334600_ciag115-B12","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for Covid-19, RSV, and influenza vaccines for 2025-2026","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082412161334600_ciag115-B13","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2026082412161334600_ciag115-B14","author":"Sch\u00fcnemann"},{"key":"2026082412161334600_ciag115-B15","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-024-01091-1","article-title":"Evaluating the effectiveness of mRNA-1273.815 against COVID-19 hospitalization among adults aged \u226518 years in the United States","volume":"14","author":"Wilson","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026082412161334600_ciag115-B16","doi-asserted-by":"crossref","first-page":"127010","DOI":"10.1016\/j.vaccine.2025.127010","article-title":"Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged \u226518 years with end stage kidney disease - United States, September 2023-April 2024","volume":"55","author":"Payne","year":"2025","journal-title":"Vaccine"},{"key":"2026082412161334600_ciag115-B17","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1038\/s41467-024-53842-w","article-title":"Effectiveness of BNT162b2 XBB vaccine in the US veterans affairs healthcare system","volume":"15","author":"Caffrey","year":"2024","journal-title":"Nat Commun"},{"key":"2026082412161334600_ciag115-B18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.15585\/mmwr.mm7312a5","article-title":"Interim effectiveness of updated 2023-2024 (monovalent XBB.1.5) COVID-19 vaccines against COVID-19-associated hospitalization among adults aged \u226518 years with immunocompromising conditions - VISION network, September 2023-February 2024","volume":"73","author":"Link-Gelles","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026082412161334600_ciag115-B19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15585\/mmwr.mm7406a1","article-title":"Interim estimates of 2024-2025 COVID-19 vaccine effectiveness among adults aged \u226518 years - VISION and IVY networks, September 2024-January 2025","volume":"74","author":"Link-Gelles","year":"2025","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026082412161334600_ciag115-B20","doi-asserted-by":"crossref","first-page":"e2517402","DOI":"10.1001\/jamanetworkopen.2025.17402","article-title":"Estimated 2023-2024 COVID-19 vaccine effectiveness in adults","volume":"8","author":"Link-Gelles","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026082412161334600_ciag115-B21","doi-asserted-by":"crossref","first-page":"102995","DOI":"10.1016\/j.eclinm.2024.102995","article-title":"Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platform","volume":"79","author":"Nguyen","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026082412161334600_ciag115-B22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12916-024-03457-1","article-title":"Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England","volume":"22","author":"Chen","year":"2024","journal-title":"BMC Med"},{"key":"2026082412161334600_ciag115-B23","doi-asserted-by":"crossref","first-page":"2295979","DOI":"10.1080\/07853890.2023.2295979","article-title":"SARS-CoV-2 vaccination in inflammatory bowel disease patients is not associated with flares: a retrospective single-centre Swiss study","volume":"56","author":"Rossier","year":"2024","journal-title":"Ann Med"},{"key":"2026082412161334600_ciag115-B24","doi-asserted-by":"crossref","first-page":"2358575","DOI":"10.1080\/21645515.2024.2358575","article-title":"Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events","volume":"20","author":"Li","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026082412161334600_ciag115-B25","doi-asserted-by":"crossref","first-page":"e3587","DOI":"10.1002\/brb3.3587","article-title":"The effect of COVID-19 vaccination on multiple sclerosis activity as reflected by MRI","volume":"14","author":"Ganelin-Cohen","year":"2024","journal-title":"Brain Behav"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag115\/67111531\/ciag115.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_3\/i111\/67111531\/ciag115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_3\/i111\/67111531\/ciag115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:16:18Z","timestamp":1787588178000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/Supplement_3\/i111\/8497524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":25,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2026,2,25]]},"published-print":{"date-parts":[[2026,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag115","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2026,2,25]]}}}